青少年和成人进食障碍筛查:美国预防服务工作组证据报告与系统综述
本系统综述纳入57项研究(N=10773),未发现直接评估筛查获益与危害的研究。SCOFF问卷(切点≥2)在成人中汇总敏感度84%、特异度80%。无干预试验纳入筛查检出人群;引导式自助、赖氨酸安非他明和托吡酯对转诊的暴食障碍人群可减轻症状严重度,但药物治疗也伴随危害。
要点
- 无研究直接评估进食障碍筛查的获益与危害。
- SCOFF问卷切点≥2在成人中检测进食障碍的汇总敏感度84%、特异度80%。
- 赖氨酸安非他明和托吡酯可减轻暴食障碍症状严重度,但伴有不良事件。
核心结论
- 无研究直接评估筛查的获益与危害;SCOFF问卷在成人中检测进食障碍具有足够准确度;无治疗试验纳入筛查检出人群;引导式自助、赖氨酸安非他明和托吡酯对转诊的暴食障碍人群可有效减轻症状严重度,但药物治疗也伴随危害。
研究设计与样本
- 系统综述纳入57项研究(N=10 773),其中3项(n=1073)仅限于青少年(平均或中位年龄14-15岁);检索MEDLINE、Cochrane Library、PsycINFO和试验注册库至2020年12月19日,监测至2022年1月1日。
主要发现
- SCOFF问卷(切点≥2)在成人中(10项研究,n=3684)汇总敏感度84%(95%CI,74%至90%),汇总特异度80%(95%CI,65%至89%)。
- 赖氨酸安非他明治疗暴食障碍(4项RCT;n=900)在YBOCS-BE量表上症状严重度降低幅度大于安慰剂(汇总均差-5.75[95%CI,-8.32至-3.17])。
- 托吡酯治疗暴食障碍的2项RCT(n=465)显示YBOCS-BE评分降低幅度大于安慰剂,从-6.40(95%CI,-8.16至-4.64)到-2.55(95%CI,-4.22至-0.88)。
- 引导式自助治疗暴食障碍(5项研究,n=391)在症状严重度改善上优于对照(汇总标准化均差-0.96[95%CI,-1.26至-0.67])。
- 与安慰剂相比,赖氨酸安非他明与口干、头痛和失眠发生率更高相关,托吡酯与感觉异常、味觉倒错、意识模糊和注意力困难发生率更高相关。
关键数值与推荐
- SCOFF问卷切点≥2用于成人进食障碍检测:汇总敏感度84%(95%CI,74%至90%),汇总特异度80%(95%CI,65%至89%)。
- 赖氨酸安非他明对比安慰剂在YBOCS-BE上的汇总均差为-5.75(95%CI,-8.32至-3.17)。
- 托吡酯对比安慰剂在YBOCS-BE上的均差范围为-6.40(95%CI,-8.16至-4.64)至-2.55(95%CI,-4.22至-0.88)。
- 引导式自助对比对照在进食障碍症状严重度上的汇总标准化均差为-0.96(95%CI,-1.26至-0.67)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无研究直接评估筛查的获益与危害。
- 无治疗试验纳入筛查检出人群。
- 其他干预措施的证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Eating disorders are associated with adverse health and social outcomes. OBJECTIVE: To review the evidence on screening for eating disorders in adolescents and adults to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, Cochrane Library, PsycINFO, and trial registries through December 19, 2020; surveillance through January 1, 2022. STUDY SELECTION: English-language studies of screening test accuracy, randomized clinical trials (RCTs) of screening or interventions for eating disorders in populations with screen-detected or previously untreated eating disorders (trials limited to populations who are underweight were ineligible). DATA EXTRACTION AND SYNTHESIS: Dual review of abstracts, full-text articles, and study quality. Meta-analysis of test accuracy studies and intervention trials. MAIN OUTCOMES AND MEASURES: Test accuracy, eating disorder symptom severity, quality of life, depression, and harms. RESULTS: Fifty-seven studies were included (N = 10 773); 3 (n = 1073) limited to adolescents (mean or median age, 14-15 years). No study directly evaluated the benefits and harms of screening. Seventeen studies (n = 6804) evaluated screening test accuracy. The SCOFF questionnaire (cut point ≥2) had a pooled sensitivity of 84% (95% CI, 74% to 90%) and pooled specificity of 80% (95% CI, 65% to 89%) in adults (10 studies, n = 3684). Forty RCTs (n = 3969) evaluated interventions for eating disorders; none enrolled a screen-detected population. Lisdexamfetamine for binge eating disorder (4 RCTs; n = 900) was associated with larger reductions in eating disorder symptom severity on the Yale-Brown Obsessive Compulsive Scale modified for binge eating (YBOCS-BE) than placebo (pooled mean difference, -5.75 [95% CI, -8.32 to -3.17]). Two RCTs (n = 465) of topiramate for binge eating disorder found larger reductions in YBOCS-BE scores associated with topiramate than placebo, from -6.40 (95% CI, -8.16 to -4.64) to -2.55 (95% CI, -4.22 to -0.88). Nine pharmacotherapy trials (n = 2006) reported on harms. Compared with placebo, lisdexamfetamine was associated with higher rates of dry mouth, headache, and insomnia, and topiramate was associated with higher rates of paresthesia, taste perversion, confusion, and concentration difficulty. Twenty-four trials (n = 1644) assessed psychological interventions. Guided self-help for binge eating disorder improved eating disorder symptom severity more than control (pooled standardized mean difference, -0.96 [95% CI, -1.26 to -0.67]) (5 studies, n = 391). Evidence on other interventions was limited. CONCLUSIONS AND RELEVANCE: No studies directly assessed the benefits and harms of screening. The SCOFF questionnaire had adequate accuracy for detecting eating disorders among adults. No treatment trials enrolled screen-detected populations; guided self-help, lisdexamfetamine, and topiramate were effective for reducing eating disorder symptom severity among referred populations with binge eating disorder, but pharmacotherapies were also associated with harms.
引用
- Feltner C, Peat C, Reddy S, et al. Screening for Eating Disorders in Adolescents and Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022. PMID: 35289875. doi:10.1001/jama.2022.1807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。